WO1991019707A3 - Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones - Google Patents

Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones Download PDF

Info

Publication number
WO1991019707A3
WO1991019707A3 PCT/US1991/004140 US9104140W WO9119707A3 WO 1991019707 A3 WO1991019707 A3 WO 1991019707A3 US 9104140 W US9104140 W US 9104140W WO 9119707 A3 WO9119707 A3 WO 9119707A3
Authority
WO
WIPO (PCT)
Prior art keywords
ones
antiatherosclerotic
benzoxazine
benzopyran
antithrombotic
Prior art date
Application number
PCT/US1991/004140
Other languages
French (fr)
Other versions
WO1991019707A2 (en
Inventor
Ronald B Gammill
Thomas M Judge
Joel Morris
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Priority to EP91911326A priority Critical patent/EP0525123B1/en
Priority to DE69127690T priority patent/DE69127690T2/en
Publication of WO1991019707A2 publication Critical patent/WO1991019707A2/en
Publication of WO1991019707A3 publication Critical patent/WO1991019707A3/en
Priority to GR970403134T priority patent/GR3025485T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/20—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

This invention relates to compounds of formula (I) which are useful in association with a pharmaceutical carrier as antiatherosclerotic agents. In addition, various compounds of formula (I) are useful inhibitors of cell proliferation.
PCT/US1991/004140 1990-06-20 1991-06-18 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones WO1991019707A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP91911326A EP0525123B1 (en) 1990-06-20 1991-06-18 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DE69127690T DE69127690T2 (en) 1990-06-20 1991-06-18 ANTIATHEROSCLEROTIC AND ANTITHROMBOTIC 1-BENZOPYRAN-4-ON AND 2-AMINO-1,3-BENZOXAZINE-4-ON DERIVATIVES
GR970403134T GR3025485T3 (en) 1990-06-20 1997-11-26 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54112690A 1990-06-20 1990-06-20
US541,126 1990-06-20

Publications (2)

Publication Number Publication Date
WO1991019707A2 WO1991019707A2 (en) 1991-12-26
WO1991019707A3 true WO1991019707A3 (en) 1992-03-05

Family

ID=24158277

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/004140 WO1991019707A2 (en) 1990-06-20 1991-06-18 Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Country Status (10)

Country Link
EP (1) EP0525123B1 (en)
JP (1) JPH05509302A (en)
AT (1) ATE158288T1 (en)
AU (1) AU7998291A (en)
CA (1) CA2081577A1 (en)
DE (1) DE69127690T2 (en)
DK (1) DK0525123T3 (en)
ES (1) ES2106783T3 (en)
GR (1) GR3025485T3 (en)
WO (1) WO1991019707A2 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474994A (en) * 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (en) * 1992-02-25 1995-09-25 Recordati Chem Pharm BENZOPYRANIC AND BENZOTHIOPYRANIC DERIVATIVES
US5605896A (en) * 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
US5633274A (en) * 1993-02-18 1997-05-27 President And Fellows Of Harvard College Cancer treatments
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB9306062D0 (en) * 1993-03-24 1993-05-12 Lilly Industries Ltd Pharmaceutical compounds
EP0619314A1 (en) * 1993-04-09 1994-10-12 Eli Lilly And Company 4-Phenyl-4H- naphtho(2,1-b)pyran derivatives and their pharmaceutical use
US5556871A (en) * 1995-04-24 1996-09-17 President & Fellows Of Harvard College Method for treating epithelial precancerous lesions with topical inidazoles
US6180625B1 (en) 1998-03-24 2001-01-30 Novo Nordisk A/S Heterocyclic compounds regulating clotting
DE19850131A1 (en) * 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon and chromanone derivatives
WO2000051992A1 (en) * 1999-03-04 2000-09-08 E.I. Du Pont De Nemours And Company Fused bicyclic oxazinone and thiazinone fungicides
JP4820518B2 (en) 2000-01-24 2011-11-24 アストラゼネカ アクチボラグ Morpholino-substituted compound therapeutics
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
US6924376B2 (en) 2002-04-17 2005-08-02 Cytokinetics, Inc. Compounds, compositions and methods
ATE423110T1 (en) 2002-07-17 2009-03-15 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING CELLULAR PROLIFERATIVE DISEASES
EP1537102A4 (en) 2002-08-16 2010-12-08 Astrazeneca Ab Inhibition of phsphoinostide 3-dinase beta
CN101260104A (en) * 2002-08-16 2008-09-10 阿斯利康(瑞典)有限公司 Inhibition of phosphoinositide 3-kinase beta
BRPI0409063A (en) * 2003-04-03 2006-03-28 Semafore Pharmaceuticals Inc pro pi-3 kinase inhibitor medications
KR101099409B1 (en) * 2003-06-06 2011-12-27 아렉시스 악티에볼라그 Use of fused heterocyclic compounds as scce inhibitors for the treatment of skin conditions or cancer
DE602004026071D1 (en) 2003-08-13 2010-04-29 Kudos Pharm Ltd AMINOPYRONE AND ITS USE AS ATM INHIBITORS
BRPI0515498A (en) 2004-09-20 2008-07-29 Kudos Pharm Ltd dna-pk inhibitors
JP2008529995A (en) 2005-02-09 2008-08-07 クドス ファーマシューティカルズ リミテッド ATM inhibitor
AR053358A1 (en) 2005-04-15 2007-05-02 Cancer Rec Tech Ltd DNA INHIBITORS - PK
JPWO2009038064A1 (en) * 2007-09-19 2011-01-06 株式会社医薬分子設計研究所 Heterocyclic derivatives having type I 11β-hydroxysteroid dehydrogenase inhibitory activity
CA2712022A1 (en) * 2008-01-25 2009-01-30 Astrazeneca Ab Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
EP2808322B1 (en) * 2012-01-26 2017-08-23 Daiichi Sankyo Company, Limited Chromone derivative having osteogenesis promoting effect
WO2023016521A1 (en) * 2021-08-12 2023-02-16 上海赛默罗生物科技有限公司 Substituted triazole derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092416A (en) * 1975-12-09 1978-05-30 Boehringer Mannheim Gmbh Benzopyrone derivatives exhibiting anti-allergic activity
EP0248420A2 (en) * 1986-06-04 1987-12-09 Daiichi Seiyaku Co., Ltd. Benzopyran derivatives
WO1990006921A1 (en) * 1988-12-21 1990-06-28 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4092416A (en) * 1975-12-09 1978-05-30 Boehringer Mannheim Gmbh Benzopyrone derivatives exhibiting anti-allergic activity
EP0248420A2 (en) * 1986-06-04 1987-12-09 Daiichi Seiyaku Co., Ltd. Benzopyran derivatives
WO1990006921A1 (en) * 1988-12-21 1990-06-28 The Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, volume 87, no. 15, 10 October 1977 (Columbus, Ohio, US) A. Ermili et al.: "Chemical and pharmacological research on pyran derivatives. Note VIII. Synthesis of 2-(dialkylamino)-7-methoxychromones and their derivatives", see page 588, abstract 117750g, & Farmaco, Edizione Scientifica 1977, 32(5), 375-387 (cited in the application) *
European Journal of Medicinal Chemistry, volume 23, no. 3, May-June 1988 (Paris, FR) M. Mazzei et al.: "Synthesis and anti-platelet activity of some 2-(dialkylamino)chromones", pages 237-242, see the whole document (cited in the application) *
Journal of Heterocyclic Chemistry, volume 18, no. 4, June 1981, Hetero Corp. (Provo, US) J.R. Bantick et al.: "Synthesis of 2-aminochromones. Studies on the nucleophilic displacement of sulphinyl and sulphonyl groups in the 2-position of 5,8-dimethoxychromone", pages 678-684, see the whole article (cited in the application) *

Also Published As

Publication number Publication date
GR3025485T3 (en) 1998-02-27
EP0525123B1 (en) 1997-09-17
EP0525123A1 (en) 1993-02-03
DE69127690D1 (en) 1997-10-23
WO1991019707A2 (en) 1991-12-26
AU7998291A (en) 1992-01-07
DE69127690T2 (en) 1998-02-12
JPH05509302A (en) 1993-12-22
ES2106783T3 (en) 1997-11-16
DK0525123T3 (en) 1998-05-04
ATE158288T1 (en) 1997-10-15
CA2081577A1 (en) 1991-12-21

Similar Documents

Publication Publication Date Title
AU7998291A (en) Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
DE58906377D1 (en) Difluormethylverbindungen.
ATE148130T1 (en) TYPE IV DIPEPTIDYL AMINOOPEPTIDASE INHIBITORS
BG101112A (en) The use of heterocyclic compounds
CA2396738A1 (en) Thiazole derivatives as active superoxide radical inhibitors
IL129068A0 (en) Sulfinic acid derivatives and their preparation and use
NZ233735A (en) Heterocyclic substituted aminophenol derivatives
MY131595A (en) Heterocyclically substituted phenyl-cyclohexane- carboxylic acid derivatives
MX9604367A (en) Novel hydroxypyridinones.
GR3018304T3 (en) Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4h-pyran-4-ones.
NZ237884A (en) N-hydroxy-n-linolanyl (chromanyl or quinolinyl) alkyl urea and amide derivatives, preparation and pharmaceutical compositions thereof
TW223630B (en) Retroviral protease inhibitors
MY103241A (en) Imidazole and 1,2,4 triazole derivatives
AU632846B2 (en) Substituted n-(quinolin-2-yl-methoxy)benzyl-sulphonyl-ureas
MY132057A (en) Quinoxalinones, a process for their preparation and their use
MY117934A (en) Process for the preparation of n-methyl-3-(1-methyl-4- piperidinyl)-1h-indole-5-ethanesulphonamide
DK0490816T3 (en) Fluorine Compounds as Aromatase Inhibitors.
SI0861250T1 (en) Amidine and isothiourea derivatives as inhibitors of nitric oxide synthase
AU6306190A (en) Novel substituted alkyl piperidines and their use as inhibitors of cholesterol synthesis
MX9603348A (en) Novel indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase.
GR3023427T3 (en) Heteroarylmethylbenzols aromatase inhibitors
PL313594A1 (en) Triaryl ethylene derivatives for therapeutic applications
TW329388B (en) Intraocular irrigating solution
NO912420L (en) ANTIATHEROSCLEROTIC AND ANTITROMOBOTIC 1-BENZOPYRANE-4-ONER AND 2-AMINO-1,3-BENZOKSAZIN-4-ONER.
PL312966A1 (en) Derivatives of thiocarbamoil

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO PL RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1991911326

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2081577

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991911326

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991911326

Country of ref document: EP